Financial Calendar

Upcoming events

Credit Suisse Healthcare Conference, London, management participation

Daiwa/Bernstein Investment Conference, Tokyo, management participation


Investor information

This may not be the latest available data

Financial results

Total revenue
$23.0bn
↓ 5% at CER

Core earnings per share
$4.31
↓ 5% at CER

Annual Report websites

Our Annual Report provides a wide range of information about our global business and how we are working, both within the company and in partnership with others, to meet complex healthcare challenges and deliver life-changing medicines for people worldwide.

 

Investor notes

I/O combo data updated at SITC - durvalumab plus tremelimumab combination data in lung cancer (6 November 2015)

AstraZeneca Investor Relations Team's Briefing Note regarding updated combination data presented at the Society for Immunotherapy in Cancer (SITC) on Friday 6 November 2015.

AstraZeneca refines its financial reporting in line with evolving business model (6 March 2015)

AstraZeneca announced an update to the presentation of its Statement of Comprehensive Income, which will see revenue from externalisation becoming more visible to enhance transparency for investors.

Accounting for the US Branded Pharmaceutical Fee (7 January 2015)

In mid 2014 the Internal Revenue Service issued final regulations that affected how the annual branded pharmaceutical fee, imposed by the health care reform legislation in 2010 is recognised. As a result, entities covered by the legislation will now accrue for the obligation as each sale occurs. AstraZeneca recorded a catch-up charge to SG&A, reflecting this new basis, as part of its Q3 2014 results.

Diabetes alliance transaction overview (19 December 2014)

Contact us

Investor enquiries

Main Contacts

Thomas Kudsk Larsen

Craig Marks

Finance, Fixed Income, M&A

Henry Wheeler

Oncology

Mitchell Chan

Oncology

Lindsey Trickett

Cardiovascular & Metabolic Diseases

Nick Stone

Respiratory

Christer Gruvris

Autoimmunity, Neuroscience & Infection

US general enquiries

  • Annual Reports

    Our Annual Report provides a wide range of information about our global business.


  • Shareholder FAQs

    Answers to frequently asked shareholder questions.


  • Our Pipeline

    Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development